Under the Paperwork Reduction Act of 1995, no persons are required to

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10575888		
Filing Date		2006-04-13		
First Named Inventor Yasu		niro Yamakoshi		
Art Unit		2811		
Examiner Name				
Attorney Docket Number		OGOSHSHISA		

				U.S.	PATENTS		Remove		
			Kind Code <sup>1</sup>	Issue Date Name of Patentee or Applicant			Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		
	1	4159909		1979-07-03	Wilson				
	2	4094761		1978-06-13	Wilson		<u> </u>		
If you wish	to a	dd additional U.S. Paten	t citatio	n information pl	lease click the Add button.		Add		
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Releva		Lines where ges or Relevan	
	1	20040256035	A1	2004-12-23	Yamakoshi et al.				
	2	20060037680	A1	2006-02-23	Yamakoshi				
	3	20060088436	A1	2006-04-27	Okabe				
	4	20060292028	A1	2006-12-28	Shindo et al.				
If you wish	to ac	L dd additional U.S. Publis			n information please click the Ad	l d button	Add		

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10575888	
Filing Date		2006-04-13	
First Named Inventor	Yasuhiro Yamakoshi		
Art Unit		2811	
Examiner Name			
		OCOCUENICA	

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	TS
	1	11-117061	JP	A	1999-04-27	Kuboi et al.		
	2	09-074097	JP	A	1997-03-18	Yanagida		
If you wish	h to a	i dd additional Foreign P	atent Document	citation	information pl	lease click the Add butto	n Add	
			NON-PATE	NT LITE	ERATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No						Ţ5	
	1	ESP@CENET DATABA	SE, One page En	glish Abe	stract of JP 56-1	10230, September 1, 1981		
	2	ESP@CENET DATABA	SE, One page En	glish Abe	stract of JP 2000	0-169922, June 20, 2000		
	3	ESP@CENET DATABA	SE, One page En	glish Abe	stract of JP 2000	0-169957, June 20, 2000		
	4	ESP@CENET DATABA	SE, One page En	glish Abe	stract of JP 2008	3-169923, June 20, 2000		
	5	ESP@CENET DATABA	SE, One page En	glish Abe	stract of JP 200	1-011612, January 16, 2001	ı	
If you wish	h to a	d additional non-pater	t literature docu	ment cit	tation informat	ion please click the Add	button Add	

#### 

EXAMINER SIGNATURE							
Examiner Signature		Date Considered					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

See Kinc Ooke of USPTO Patent Documents at www.ISPTO.GOV or MPEP 901.04. I Enter office that issued the document, by the Involvation (WIPO Standard S13.) "Extra office This papers operated counters, the involvation of the year of the integer or impreced the serial running represent the serial running of the Empirer name precede the serial running of the Empirer name precede the serial running of the Empirer name precedes the serial running of the Empirer name of the Empirer

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10575888		
Filing Date		2006-04-13		
First Named Inventor	Yasuhiro Yamakoshi			
Art Unit		2811		
Examiner Name				
Attorney Docket Number		OGOSH52USA		

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make	the appropriate selection(s):
---------------	----------	------------------	-------------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

▼ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/William Bak/	Date (YYYY-MM-DD)	2007-01-03		
Name/Print	William Rak	Registration Number	37277		

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.